Navigation Links
Colorectal cancer risk increases in prostate cancer patients on androgen deprivation therapy
Date:11/10/2010

Men taking androgen deprivation therapy (ADT) for prostate cancer may have an increased risk of colorectal cancer, according to a study published online November 10 in The Journal of the National Cancer Institute.

Androgen deprivation therapy is a widely-prescribed treatment in men with prostate cancer, although its usage for low-risk disease remains controversial, given the adverse side effects, including osteoporosis, cardiovascular disease, diabetes and obesity; the last two are risk factors for colorectal cancer.

To determine whether prostate cancer patients taking androgen deprivation therapy are at an increased risk of colon cancer, Silke Gillessen, M.D., of the Cantonal Hospital in St. Gallen, Switzerland, and colleagues, did an observational study of men with prostate cancer identified through the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute. Specifically, they identified 107,859 men aged 67 years or older who were diagnosed with prostate cancer between 1993 and 2002, with follow-up through 2004. The men received the ADT either in the form of gonadotropin-releasing hormone (GnRH) agonists, or an orchiectomy.

The researchers found that after adjustment for confounding variables such as age and socio-economic status, there was a 30-40% relative increase in the rate of colorectal cancer among the men treated with ADT compared with those who were not. Furthermore, the longer the men took ADT, the greater their risk of developing colorectal cancer. However, further study would be needed to determine the risk with treatment over longer periods than could be observed in this study.

The authors write that the study results could have "important implications" for men with prostate cancer taking ADT, especially those with localized, slow-growing disease, for whom the duration of ADT is generally longer.

In an accompanying editorial, Jennifer H. Lin, Ph.D., and Edward Giovannucci, M.D., of Brigham and Women's Hospital in Boston write that the study shows that an elevated risk of colorectal cancer may be an additional consideration in the decision to use ADT, especially given the side effects and their effect on quality of life.


'/>"/>

Contact: Kristine Crane
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Statins did not reduce colorectal cancer in WHI analysis
2. Colorectal cancer survival advantage in MUTYH-associated polyposis
3. Healthy Living Can Prevent Nearly 25% of Colorectal Cancers
4. Colorectal cancer patients with gene mutation show better response to cancer agent
5. Colorectal cancer screening can be expanded by offering it during mammography visits
6. Virtual colonoscopy option could improve colorectal cancer screening rates, patient survey suggests
7. Virtual colonoscopy and teleradiology bring colorectal cancer screening to patients in rural areas
8. Type 2 diabetes and insulin use are associated with colorectal cancer in men
9. Notable racial disparities in diagnosis, treatment and outcomes of colorectal cancer
10. Lack of insurance coverage remains obstacle to wider colorectal cancer screening with CT colonography
11. Colorectal cancer screening in Canada is cost-effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... 2017 , ... Every year, thousands of dedicated Higher Education and K12 professionals ... is coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... organizations that already work hand-in-hand on an Innovation Collaboration program, have signed a ... quality, experience and cost of the care members and patients receive. The agreement ...
(Date:7/24/2017)... ... ... Anyone who uses scales know they have limits; a small kitchen scale ... scale to dispense medication. The first example is an issue of capacity, while the ... important to have the right balance for the process. METTLER TOLEDO’s new white paper, ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... solution focused on delivering end-to-end sleep health care at scale, indicates record-breaking ... shows that adherence rates for positive airway pressure (PAP) therapy, the most widely ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... received the prestigious StorErotica “Consumer’s Choice” Award, for favorite sex toy. Created in ... 11th annual StorErotica Awards to be consumer voted. The Magic Wand Rechargeable won ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... 2017 ThriveRx, the nutrition division of Diplomat Specialty Infusion Group, ... on nutrition support. To celebrate its anniversary, ThriveRx recently launched ... fresh new look with improved organization to create the best user experience ... ... "We,ve made several great ...
(Date:7/5/2017)... 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... received approval from the Israel Securities Authority to dual-list its ... common stock will commence trading on the TASE on July ... market capitalization of the Company, it is expected that Oramed ...
(Date:7/5/2017)... July 5, 2017   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade cell and tissue ... media ("BioLife"), today announced that it has reached an ... and largest shareholder, to modify its existing credit facility ... the modification, WAVI agreed to exchange its existing $4.25 ...
Breaking Medicine Technology: